Confirmation of a broader link between CCR5 deficiency and augmented incidence and severity of flaviviral disease would add to the concern of potential adverse outcomes associated with CCR5 antagonist use, in view of the large number of human infections inflicted by the different pathogenic members of the Flavivirus genus, and their widespread global distribution (reviewed in [12]. This evidence concerns the gene CCR5 and infection.